主页 > 医学前沿 >
【drug-news】强生抗癌药＂无效＂退款正式起动!
Meter Set to Run on J&J’s Cash-Back Deal
Posted by Peter Loftus
Johnson & Johnson offered the U.K.’s health service a money-back guarantee for the cancer drug Velcade in a last-ditch attempt to get it accepted by the government-run system for payment. Now the pathbreaking deal proposed earlier this year is about to come due.
In a matter of weeks, J&J is expected to be on the hook for the full cost of Velcade treatment for multiple myeloma patients who don’t improve sufficiently after four cycles of treatment with medicine.
J&J dug deep after the U.K.’s National Institute for Health and Clinical Excellence, or NICE, concluded Velcade’s benefit didn’t justify its cost - about GBP3,000 per cycle of treatment, or more than $6,000. Many patients taking Velcade show little or no improvement, NICE noted.
The rebate changed the equation, and the U.K. relented. “For those who may get a full response or a partial response…it’s a cost-effective intervention for the National Health Service,” Andrew Dillon, chief executive of NICE, told Dow Jones Newswires. “Narrowing down to patients getting the best response makes it worth it.” A government proposal formalizing the deal is expected to become final on Oct. 24.
The Velcade rebate program is the first of its kind in the U.K. and may be a harbinger of things to come there and elsewhere. Velcade has been available in the U.S. since 2003 and in Europe since 2004. It was co-developed by Millennium Pharmaceuticals and J&J. The companies co-promote it domestically and J&J handles those chores alone overseas. 认领，48h提交。 Johnson & Johnson offered the U.K.’s health service a money-back guarantee for the cancer drug Velcade in a last-ditch attempt to get it accepted by the government-run system for payment. Now the pathbreaking deal proposed earlier this year is about to come due.
强生公司为保证其抗癌药物万珂的疗效向英国卫生机构提供了一笔保证金，作为万珂进入政府支付系统的最后一招。现在，这项今年早期提出的开创性的交易马上就要实施。
In a matter of weeks, J&J is expected to be on the hook for the full cost of Velcade treatment for multiple myeloma patients who don’t improve sufficiently after four cycles of treatment with medicine.
在大约的几周内，强生公司将为那些对使用了万珂治疗四个疗程治疗后的而对疗效感到不满的多发性骨髓瘤病人承担全部费用。
J&J dug deep after the U.K.’s National Institute for Health and Clinical Excellence, or NICE, concluded Velcade’s benefit didn’t justify its cost - about GBP3,000 per cycle of treatment, or more than $6,000. Many patients taking Velcade show little or no improvement, NICE noted.
强生公司在英国国立健康和临床专家研究院调查后对万珂进行了深入分析，得出万珂的利润与它的成本不对等的结论，3000英镑甚至6000英镑每疗程的治疗。许多服用万珂的病人的病症几乎没有得到改善。
The rebate changed the equation, and the U.K. relented. “For those who may get a full response or a partial response…it’s a cost-effective intervention for the National Health Service,” Andrew Dillon, chief executive of NICE, told Dow Jones Newswires. “Narrowing down to patients getting the best response makes it worth it.” A government proposal formalizing the deal is expected to become final on Oct. 24.
退款改变了这一等式，“项目针对于那些完全有效的和有部分疗效的。。。这是值得国家卫生机构介入的，Andrew Dillon, 英国国立健康和临床专家研究院的执行总裁对Dow Jones Newswires说，“对有疗效病人的限制使得这项计划变得有价值。”政府关于此项计划的正式批文将于10月24日前下达。
The Velcade rebate program is the first of its kind in the U.K. and may be a harbinger of things to come there and elsewhere. Velcade has been available in the U.S. since 2003 and in Europe since 2004. It was co-developed by Millennium Pharmaceuticals and J&J. The companies co-promote it domestically and J&J handles those chores alone overseas.
万珂退款计划是在英国为首次发生的此类事件，并为今后此类事件的发生提供了预兆。万珂2003年在美国上市，2004年在欧洲上市，为千年制药公司和强生公司共同研发，两家公司共同开发国内市场，强生公司负责海外市场开发。 强生抗癌药万珂的退款计划
作为万珂进入政府支付系统的最后一招，强生公司为保证其抗癌药物万珂的疗效向英国卫生机构提供了一笔保证金，今项计划交易马上就要实施。
强生公司在英国国立健康和临床专家研究院调查后对万珂进行了深入分析，得出万珂的利润与它的成本不对等的结论，3000英镑甚至6000英镑每疗程的治疗，许多服用万珂的病人的病症几乎没有得到改善。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-06-21 05:11
医学,生命科学网